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Professor Kerstin Hall (1929-1917): Pioneer in the field of Growth Hormone and IGF 
Research 
Professor Kerstin Hall, a pioneer in the GH and IGF field, died 29 March 2017 at the age of 
87 years. She was still an active member of the medical research community, inspired 
generations of researchers in the IGF field and had an important influence on endocrinology 
research in Sweden. This is a personal view of her impact. 
Kerstin Hall’s contributions to research and to the clinical practice of endocrinology reflect 
the extent of her scientific curiosity, commitment and integrity. Brilliant academically, she 
trained as a surgeon before moving into internal medicine. She held the Chair in 
Endocrinology at Karolinska Institutet (1980-1995), was a member of the Nobel Committee 
for Physiology or Medicine (Photo A: Kerstin Hall with colleagues on the Nobel Committee 
for Physiology or Medicine, approx. 1985; photographer unknown1) and a Member of the 
Royal Swedish Academy of Sciences since 1989. On being awarded the Grand Silver Medal 
at Karolinska Institutet in 2011 her “genuine interest for research, intellectual sharpness and 
breadth of knowledge” were highlighted for their importance in “driving forward 
endocrinology research in Sweden” [1]. 
In our conversations, Kerstin spoke often of the early days in IGF research, and reflected on 
the characteristics of the cultures that fostered a generation of ideas and a healthy climate 
for research and innovation. She recalled the 1960s and 70s as a time of open 
communication between research groups and, in 1972, joined Daughaday, Raben, Salmon, 
Van den Brande and Van Wyk in proposing that “sulfation factor” be given the name 
“somatomedin” [2]. Although there was competitiveness at that time, particularly between 
1 http://www.nobelprizemedicine.org/selecting-laureates/history/ 
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the somatomedin groups and those investigating the insulin-like activity of plasma, she 
perceived that problems and ideas were openly and enthusiastically discussed and, 
consequently, the field thrived. Kerstin spoke of her conscious attempts to shift the focus 
away from competition and regarded this as a valuable approach that women often bring to 
the research environment. Professor Rolf Luft created an environment at Karolinska 
Institutet that allowed Kerstin Hall to thrive as a researcher. He was her doctoral supervisor 
and a role model who allowed her to develop independence. Indeed, although she fully 
acknowledged his interest and support [3], he was not co-author on any of the publications 
included in her thesis [4-9]. 
A philosophy of open collaboration underpinned her work with industry, and Kerstin Hall 
had fruitful collaborations around GH and IGFs, first with Bertil Åberg and later Linda 
Fryklund and Anna Skottner of Kabi AB. She recalled that the work was curiosity-driven as 
well as responding to clinical need e.g. management of GH deficiency. Important 
collaborators in the clinic included Martin Ritzén in the Department of Paediatrics, 
Karolinska Hospital and later Marja Thorén in the Department of Endocrinology. There were 
also researchers from across the world working with Kerstin Hall in Stockholm in those 
earlier years, notably Kazue Takano from Japan, who was her doctoral student, and Vicki 
Sara, who joined as a postdoctoral researcher from Australia. Kerstin continued in a role of 
mentor and friend and these pioneering women often returned to Stockholm to visit her. 
With the isolation and characterisation of IGFBP-1 in the 1980s and the creation of a 
radioimmunassay in collaboration with Hans Jörnvall, Guilherme Póvoa and others [10-12], 
this somatomedin-binding protein became a key focus of her research for the rest of her 
life. Recombinant materials generously given to her by Kabi AB continue to be used for the 
IGFBP-1 assay at Karolinska Hospital, and she was quietly pleased to have made a very 
personal contribution, as the individual with multiple myeloma whose urine contained 
activity that specifically cleaved IGFBP-1 [13]. 
She stood for gender equality, and recalls how she encouraged male colleagues to share 
parental leave well before it was the norm. To many she was an intimidating figure, but not 
to those who knew her well. Kerstin was someone who defended ideals, and had the 
highest integrity, but she always saw the best in people and was quick to forgive. Perhaps 
her biggest failing was that she didn’t really like writing, although she certainly enjoyed 
analysing data (Photo B: Kerstin Hall at work in 2006, photographer ML) and discussing what 
could be written. During the last few years of her life she seemed reluctant to finalise 
manuscripts and therefore let go of the data that was her passion and kept her mind alive. 
Through a broad understanding of science and statistics, combined with sound clinical 
judgement, she was able to view problems from multiple perspectives. These qualities 
included also a willingness to share openly and to nurture the career of others through 
collaborations and mentorship. Kerstin Hall will be missed by many in the global medical 
community. 
 
Moira S. Lewitt, University of the West of Scotland, Paisley 
Anna-Lena Hulting, Karolinska Institutet, Stockholm 
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